Onkologie. 2016:10(4):161-165 | DOI: 10.36290/xon.2016.035

Metronomic chemotherapy in breast cancer

Tomáš Svoboda
Komplexní onkologické centrum FN Plzeň

Metronomic therapy is a treatment method based on a long-term administration of low drug doses (mainly cytotoxics) in shorter

intervals or continuously. It is associated with lower toxicity, however, better tolerability is not linked with treatment results worsening.

On the contrary, higher effectivity was shown in many trials. Moreover, there is a quality of live improvement and better

patient´s compliance with metronomic therapy mainly due to oral form of therapy application. So there is no wonder we can see

a rebirth of this treatment type and it´s use more frequently already now.

Keywords: metronomic therapy, chemotherapy, targeted therapy, cyclophosphamide, vinorelbin, capecitabine, cost-effectivity,

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svoboda T. Metronomic chemotherapy in breast cancer. Onkologie. 2016;10(4):161-165. doi: 10.36290/xon.2016.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer. Nature Reviews Clinical Oncology 2015; (12)11: 631-644. Go to original source... Go to PubMed...
    2. Brems-Eskildsen AS, Linnet S, Luczak A, Nielsen HA, Vestlev PM, Jensen BB, Hilling T, Dongsgaard T, Jensen CB, Neimann J, Nygaard AB, Langkjer ST. Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients? Supportive Care in Cancer 2015; (23)1: Suppl. 1: S353.
    3. Foltran L, Bertola M, Sulfaro S, Del Conte A, Baresic T, Favero A, Bassini A, Lorenzon M, Tumolo S, Saracchini S. Metronomic oral vinorelbine (VNB) for treatment of advanced breast cancer (BC) patients (pts): A retrospective analysis. European Journal of Cancer 2014; 50(Suppl. 2): S182.
    4. Holubec L, Svoboda T, Fínek J, at al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer research Vol: 29 iss:2: 667-670.
    5. Ohtani S, Fujihara M. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer. Annals of Oncology 2015; 26(Suppl. 9): ix30. Go to original source...
    6. Mateen AA, Maken RN. Metronomic oral chemotherapy in metastatic breast cancer Annals of Oncology 2015; 26(Suppl. 9): ix31. Go to original source...
    7. Montagna E, Lai A, Palazzo A, Bagnardi V, Cancello G, Iorfida M, Esposito A, Sangalli C, Munzone E, Goldhirsch A, Colleoni M. A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination. European Journal of Cancer 2015; 51(Suppl. 3): S291-S292. Go to original source...
    8. Chalasani P, Robert LB, Rado TA, Gadi VK, Kummet TD, Specht JM, Stopeck A, Linden HM. Metronomic eribulin in metastatic breast cancer. Cancer Research 2015; 75: 9(Suppl. 1). Go to original source...
    9. El Kady MS, El Nasr K, Moneam Osman MA, Ellithy M. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study. Journal of Clinical Oncology 2015; 33: 15(Suppl. 1). Go to original source...
    10. Alagizy HA, Shehata MA, Hashem TA, Abdelaziz KK, Swiha MM. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer. Hematology/ Oncology and Stem Cell Therapy 2015; 8(1): 22-27. Go to original source... Go to PubMed...
    11. Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer. Clinical Breast Cancer 2015; 15(4): 259-265. Go to original source... Go to PubMed...
    12. Orlando L, Lutrino ES, Fedele P, Quaranta A, Caliolo C, Schiavone P, Fontanella C, Nacci A, Calvani N, D'Amico M, Marino A, Mazzoni E, Rizzo P, Sponziello F, Chetr? MC, Ferrara P, Cinefra M, Cinieri S. Lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): A single center experience. Annals of Oncology 2015; 26(Suppl. 6): vi17. Go to original source...
    13. Petry V, Gagliato DM, Leal AIC, Arai RJ, Longo E, Andrade F, Ricci MD, Piato JR, Barroso-Sousa R, Hoff PM, Mano MS. Metronomic chemotherapy in the neoadjuvant setting: Results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer. Brazilian Journal of Medical and Biological Research 2015; 48(5): 479-485. Go to original source...
    14. Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 2015; 6(40): 42396-42410. Go to original source...
    15. Jian-wei L, Xiao-qing J, Li L, Yu-jie W, Zhi-min S, Zhen-zhou S, Zhong-hua W, Xi-chun H, Guang-yu L. Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors. European Journal of Cancer 2015; 51(Suppl. 3): S281. Go to original source...
    16. Foltran L, Bertola M, Sulfaro S, Del Conte A, Baresic T, Favero A, Bassini A, Lorenzon M, Tumolo S, Saracchini S. Metronomic oral vinorelbine (VNB) for treatment of advanced breast cancer (BC) patients (pts): A retrospective analysis. European Journal of Cancer 2014; 50(Suppl. 2): S182.
    17. Rojas KI, Manso L, Sepúlveda JM, Mendiola C, Pascual T, Ciruelos E, Paz-Ares L. Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institucion experience. Journal of Clinical Oncology 2015; 33: 15(Suppl. 1). Go to original source...
    18. Perroud HA, Alasino CM, Rico MJ, Mainetti LE, Queralt F, Pezzotto SM, Rozados VR, Graciela Scharovsky O. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: Clinical outcomes and biomarkers of response. Cancer Chemotherapy and Pharmacology 2016; 77(2): 365-374. Go to original source... Go to PubMed...
    19. Perroud HA, Alasino CM, Rico MJ, Mainetti LE, Menacho-Marquez M, Queralt F, Rozados VR, Pezzotto SM, Scharovsky OG. Objective evaluation of quality of life in patients with advanced breast cancer treated with metronomic chemotherapy. European Journal of Cancer 2015; 51(Suppl. 3): S225. Go to original source...
    20. Otsuka H, Fujii T, Toh U, Iwakuma N, Takahashi R, Mishima M, Takenaka M, Kakuma T, Tanaka M, Shirouzu K. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast Cancer 2015; 22(4): 335-342. Go to original source... Go to PubMed...
    21. Burdette-Radoux S, Holmes CE, Khan FB, Dittus K, Wilson KM, Wood M. Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients without pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer. Journal of Clinical Oncology 2013; 31(26): Suppl. 1. Go to original source...
    22. Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J, Di L, Song G, Che L, Jia J, Zhou X, Yang H, Lyerly HK. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45) Clinical and Translational Oncology 2016; 18(1): 82-87. Go to original source... Go to PubMed...
    23. Parra K, Vidal C, Valenzuela P, Jallad S, Rodriguez G, Felder MS, Lerma N, Bocci G, Emmenegger U, Kirken RA, Francia G. Evaluation of CTLA-4 blockage with sequential metronomic chemotherapy for the treatment of preclinical breast cancer. Cancer Research 2014; 74(19): Suppl. 1. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.